Physician profile
Maria Bernardo
NPI 1487762043
$829.07
in general payments reported to CMS, 2019-2025
13 companies · $59.92 in 2025
The $59.92 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $46.72 · 2021: $168 · 2022: $103 · 2023: $138 · 2024: $117 · 2025: $59.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $236.43 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $113.62 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $99.17 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $72.23 | 2019-2022 | |
| Genentech USA, INC. | $59.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $58.78 | 2019-2021 | |
| Seqirus USA INC | $55.29 | 2024-2025 | Flucelvax |
| Novartis Pharmaceuticals Corporation | $33.08 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $28.28 | 2019 | |
| Pfizer INC. | $27.08 | 2019-2021 | |
| Shire North American Group INC | $16.85 | 2019 | |
| Neos Therapeutics, LP | $15.95 | 2019 | |
| Merck Sharp & Dohme LLC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Bernardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.